News

In Phase 3 of ENERGIZE-T, Agios Pharmaceuticals’ drug mitapivat successfully boosted hemoglobin levels in some patients with thalassemia, bringing the company closer to potential approval for the first oral treatment …

Multiple Biopharma giants have announced substantial investments in France under the country’s “Choose France” initiative. Pfizer pledged €500 million over five years to focus on clinical research and trials, particularly …

Following their recent FDA approval and more than a decade of development, biotech firm Bluebird Bio has announced the completion of its first cell collection for their Sickle Cell Disease …

In an exciting announcement from the United Kingdom’s National Health Service (NHS), patients with Sickle Cell Disease can now be prescribed Voxelotor, a Pfizer-developed drug that can significantly improve quality …

Preliminary Phase I results for etavopivat show promising impact on sickle cell disease (SCD) in trial patients. Led by Dr. Saraf Santosh of the University of Illinois Chicago, the ongoing …

The latest results from the ongoing tests of AstraZeneca Roxadustat show that the oral drug may be a safe and effective option for patients with myelofibrosis who develop anemia due …

The FDA has approved the widespread use of @Bristol Myers Squibb’s drug Reblozyl for treating anemia in adult patients with beta-thalassemia who require regular blood transfusions and suffer from low-to-intermediate-risk …

Ongoing stage 2a clinical trials for Pfizer‘s Oxbryta (voxelotor) continue to show successful results in pediatric patients. Approved for treating SCD, the oral medication prevents red blood cells from sickle-shaping …

A Phase 2/3 multicenter study of Osivelotor has been approved to proceed by India’s Central Drugs Standard Control Organisation (CDSCO). Aimed at treating Sickle Cell Disease, the drug (GBT021601) has …